{"title":"Rational design and research progress of novel mitochondrial uncouplers.","authors":"Feihuang Qiu, Tianxiang Shang, Yungen Xu, Hongfeng Gu","doi":"10.1016/j.drudis.2026.104854","DOIUrl":"https://doi.org/10.1016/j.drudis.2026.104854","url":null,"abstract":"<p><p>Mitochondrial uncouplers have been validated as effective therapeutic agents in preclinical models of metabolic dysfunction-associated diseases, including obesity, type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular diseases and tumors. In this review, we briefly summarize the biological functions and therapeutic potential of uncouplers, with a primary focus on advances in their chemical-structural optimization. We mainly recapitulate the design optimization strategies and developmental routes of representative scaffolds among protonophore‑type uncouplers, and analyze the design approaches for cutting‑edge protein‑dependent uncouplers. Finally, we provide a critical evaluation of the current dilemmas, research trends and future research directions in the field of uncouplers to provide meaningful references for future investigations.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104854"},"PeriodicalIF":8.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application.","authors":"Simranpreet Kaur, Vancha Harish, Bushra Bashir, Kaustubh Ajit Kolekar, Sachin Kumar Singh","doi":"10.1016/j.drudis.2026.104853","DOIUrl":"10.1016/j.drudis.2026.104853","url":null,"abstract":"<p><p>Exosomes have been described as emerging nanocarriers that have potential for the targeted delivery of therapeutics. They offer many advantages over traditional drug delivery systems, such as their intrinsic biocompatibility, low immunogenicity, and prolonged circulation, as well as crossing biological barriers. This review highlights the diverse functions of exosomes in the treatment of breast cancer, with a special focus on the use of engineered exosomes as nanocarriers for the delivery of doxorubicin, paclitaxel, and nucleic acids such as small interfering RNAs and microRNAs. We also discuss the modulatory effect of exosomes on both the tumour microenvironment and anti-multidrug-resistance drug efflux mechanisms. We also cover challenges associated with the clinical translation of exosomes, including product standardisation, stability and large-scale manufacturing.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104853"},"PeriodicalIF":8.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Programmable STING-activating hydrogels for in situ cancer vaccination: Spatiotemporal design and mechanistic evidence.","authors":"Hossein Omidian, Luigi X Cubeddu","doi":"10.1016/j.drudis.2026.104851","DOIUrl":"10.1016/j.drudis.2026.104851","url":null,"abstract":"<p><p>Local hydrogels can sustain stimulator of interferon genes (STING) activation, but retention alone does not establish in situ cancer vaccination. This review evaluates STING-active hydrogels in postoperative, post-ablation, fibrotic, and regional tumor settings, emphasizing agonist pharmacology, antigen availability, tissue barriers, and spatiotemporal control. Non-hydrogel systems serve only as mechanistic comparators. We distinguish programmable behavior from passive release and assess intracellular engagement, host-cell dependence, antigen cross-presentation, tumor-specific T-cell responses, immune memory, and safety. Although selected murine studies show antitumor effects, inconsistent mechanistic controls and human STING variability constrain translation. We propose an indication-specific framework requiring matched comparators, spatial measurements, antigen-specific immunity, and human-relevant safety before claiming in situ vaccination.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104851"},"PeriodicalIF":8.7,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Everything is local: A framework for clinical global assessment in drug development.","authors":"Christopher D Breder","doi":"10.1016/j.drudis.2026.104852","DOIUrl":"10.1016/j.drudis.2026.104852","url":null,"abstract":"<p><p>The Clinical Global Impression (CGI) Scale was developed as an efficient means to capture drug effect in the burgeoning field of psychopharmacology during the 1960s and 1970s. It has also served as an anchor for scaling symptom scale results and as a regulatory endpoint. For reasons largely related to its lack of definition, disease-specific versions have been developed. The overlap between these CGIs and symptom scales raises a question as to the utility of a global scale. Future direction in this issue could be directed by increased use of the Activity of Daily Living or Functionality Scales to describe clinical meaningfulness.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104852"},"PeriodicalIF":8.7,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jason M Newman, Todd W Pascarella, Júlio C Borges, Paulo R Dores-Silva
{"title":"Target-state uncertainty in drug discovery: when precise binding data describe the wrong system.","authors":"Jason M Newman, Todd W Pascarella, Júlio C Borges, Paulo R Dores-Silva","doi":"10.1016/j.drudis.2026.104838","DOIUrl":"10.1016/j.drudis.2026.104838","url":null,"abstract":"<p><p>Binding measurements can be precise and reproducible while describing a molecular state insufficiently defined for the biological or pharmacological question. We define this problem as 'target-state uncertainty'. Experimental evidence shows that changes in conformation, assembly, post-translational modification and environment can alter ligand detection, compound ranking, affinity, function and transferability. State dependence can also be deliberately exploited when the relevant state is defined as the target. We propose target-state validation across four complementary dimensions: structure, stability, dispersity and function. This framework defines what molecular system was measured, what the resulting data can support and where their interpretation should stop.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104838"},"PeriodicalIF":8.7,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Activity Wall in Alzheimer's drug discovery: When potency optimization reaches its limits.","authors":"Carlos D Ramírez-Márquez, José L Medina-Franco","doi":"10.1016/j.drudis.2026.104846","DOIUrl":"10.1016/j.drudis.2026.104846","url":null,"abstract":"<p><p>Modern drug discovery attrition is often attributed to biological complexity or target invalidation. However, a core obstacle might lie in the industry's asymmetric focus on maximizing binding affinity at the expense of holistic molecular quality, driven by a pervasive potency bias. This produces overengineered leads that collide with an 'Activity Wall', defined here as the multifactorial barrier that prevents chemical analogs from being optimized indefinitely, in which further affinity gains cease to translate into therapeutic success. By exploring chemical space through scaffold-based constellation plots and ligand-lipophilicity efficiency, we show how structural modifications improve potency primarily via lipophilicity inflation within established scaffolds. This is illustrated by analyzing small-molecule inhibitors of two key Alzheimer's targets: beta-site APP cleaving enzyme 1 and the Tau protein.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104846"},"PeriodicalIF":8.7,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Medicine's missing memory: what AI's mathematical breakthrough reveals about biomedicine.","authors":"Noam Solomon, Mikael Dolsten, Charles H Jones","doi":"10.1016/j.drudis.2026.104850","DOIUrl":"10.1016/j.drudis.2026.104850","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104850"},"PeriodicalIF":8.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zongyao Zheng, Xu Lin, Xiang Wang, Jiayan Shen, Nengming Lin
{"title":"Crosstalk between the cell cycle and ferroptosis in tumor cells.","authors":"Zongyao Zheng, Xu Lin, Xiang Wang, Jiayan Shen, Nengming Lin","doi":"10.1016/j.drudis.2026.104848","DOIUrl":"10.1016/j.drudis.2026.104848","url":null,"abstract":"<p><p>Cell-cycle regulation shapes ferroptosis through its influences on lipid metabolism, antioxidant defenses, and stress signaling. This review examines how p53, retinoblastoma protein, cyclin-dependent kinases, and DNA damage checkpoints influence ferroptosis in cancer. We reconcile the occurrence of both sensitization and resistance following cell cycle arrest by considering cellular state, arrest duration, lipid storage, redox status, and alternative defense pathways. Drug-tolerant persister cells are distinguished from other slowly proliferating cell populations. Proposed combination treatments remain preclinical, with translation constrained by pharmacokinetics, normal tissue toxicity, tumor heterogeneity, delivery, and unvalidated biomarkers. Functional metabolic assessment is therefore needed alongside cell cycle measurements to guide the future development of therapies that target the cell cycle and ferroptosis.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104848"},"PeriodicalIF":8.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jing Yao, Jing Ma, Ming-Jie Chen, Chuanjun Song, Yan Qiao
{"title":"UHRF1-mediated epigenetic dysregulation in tumors: Mechanisms, therapeutic resistance and targeted inhibitors.","authors":"Jing Yao, Jing Ma, Ming-Jie Chen, Chuanjun Song, Yan Qiao","doi":"10.1016/j.drudis.2026.104849","DOIUrl":"10.1016/j.drudis.2026.104849","url":null,"abstract":"<p><p>Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) is a multifunctional epigenetic regulator that plays a critical role in tumorigenesis and cancer progression. However, the development of small-molecule inhibitors targeting UHRF1 remains in its early stages. This review provides a systematic overview of the molecular basis underlying the oncogenic functions of UHRF1, with a focus on its roles in epigenetic silencing, cell-cycle dysregulation, apoptosis suppression, metabolic reprogramming, signaling pathway dysregulation and immune evasion. Particular emphasis is placed on the role of UHRF1 in cancer therapeutic resistance, including resistance to chemotherapy, immunotherapy and radiotherapy. Additionally, we summarize recent advances in UHRF1-targeted small-molecule inhibitors, grade the reported compounds by the strength of the evidence for their binding mode and discuss their mechanisms of action, their therapeutic potential and the requirements for clinical translation.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104849"},"PeriodicalIF":8.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Catherine Drai, Violaine Closson Carella, Sean Barry, Ailise Carleton, Dolça Rogers, Bruno Sepodes, Joseph deCourcey, Caoimhin Concannon, Ilona Reischl Kok
{"title":"An EMA perspective on the regulatory approval of Waskyra®, the first gene therapy for the treatment of Wiskott-Aldrich syndrome.","authors":"Catherine Drai, Violaine Closson Carella, Sean Barry, Ailise Carleton, Dolça Rogers, Bruno Sepodes, Joseph deCourcey, Caoimhin Concannon, Ilona Reischl Kok","doi":"10.1016/j.drudis.2026.104847","DOIUrl":"10.1016/j.drudis.2026.104847","url":null,"abstract":"<p><p>European Union (EU) authorisation for the gene therapy medicinal product Waskyra® (etuvetidigene autotemcel; hereafter etu-cel) marks a milestone for patients living with Wiskott-Aldrich syndrome (WAS). The successful regulatory application for Waskyra by a non-profit organisation reflects not only the convincing scientific evidence supporting the authorisation, but also highlights that regulatory support is available from the European Medicines Agency (EMA) to help (small) developers manoeuvre the complexities of gene therapy medicinal product development for rare diseases. Here, we summarise the assessment by the EMA's Committees and present the key aspects underlying the positive outcome. Developers of innovative therapies addressing clear unmet medical needs are encouraged to seek early interaction with the EMA to help them design robust development programs and access supportive pathways that facilitate and accelerate development and evaluation.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104847"},"PeriodicalIF":8.7,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}